Protecting a blockbuster diabetes treatment for AstraZeneca
AstraZeneca AB
Major victories across IP venues for Volkswagen, Audi, Bentley, and Lamborghini
Audi AG; Audi of America, LLC; Automobili Lamborghini America, LLC; Automobili Lamborghini S.p.A.; Bentley Motors Limited; Bentley Motors, Inc; Volkswagen AG; Volkswagen Group of America, Inc.
No confusion in trademark victory on summary judgment for the American Retirement Association
American Retirement Association
Finnegan helps Intellia Therapeutics acquire Rewrite Therapeutics, Inc. for $45 million
Intellia Therapeutics, Inc.
Finnegan secures favorable ITC ruling related to innovative electric SUVs for BMW
BMW of North America, LLC and Bayerische Motoren Werke AG
Finnegan fights for Sony’s “exceedingly famous” mark
Sony Group Corporation
Experience
Finnegan helps Intellia Therapeutics acquire Rewrite Therapeutics, Inc. for $45 million Finnegan helps Intellia Therapeutics acquire Rewrite Therapeutics, Inc. for $45 million
Intellia Therapeutics, Inc.
Experience
Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al. Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al.
1:21-cv-01736, 1:23-cv-00554, D. Del., Judge Andrews
Experience
Protecting a blockbuster diabetes treatment for AstraZeneca Protecting a blockbuster diabetes treatment for AstraZeneca
1:18-cv-00664, D. Del., Judge Andrews
Experience
Novartis Pharmaceuticals Corporation et al. v. Fresenius Kabi USA, LLC et al. Novartis Pharmaceuticals Corporation et al. v. Fresenius Kabi USA, LLC et al.
1:21-cv-00870, D. Del., Judge Hall
Experience
Finnegan revives key Jublia® patent at the Federal Circuit Finnegan revives key Jublia® patent at the Federal Circuit
3:18-cv-13635, D.N.J., Judges Martinotti, Goodman
18-2232, Fed. Cir., Judges Newman, O'Malley, Taranto
IPR2017-00190, PTAB, Judges Mitchell, Franklin, Pollock
IPR2017-01429, PTAB, Judges Mitchell, Franklin, Pollock
Experience
Nissei ASB Co., et al. v. R&D Tool & Engineering Co. Nissei ASB Co., et al. v. R&D Tool & Engineering Co.
4:19-cv-00042, W.D. Mo., Judge Kays
Experience
Ajinomoto Co., Inc. et al. v. CJ Cheiljedang Corp. et al. Ajinomoto Co., Inc. et al. v. CJ Cheiljedang Corp. et al.
1:16-cv-03498, S.D.N.Y., Judges Gorenstein, Vyskocil
337-TA-1005, ITC, Judges Bullock, Essex
18-1590, -1629, Fed. Cir., Judges Dyk, Moore, Taranto
IPR2017-01551, -01698, PTAB, Judges Franklin, Mitchell, Moore, Sawert, Yang
Experience
District court finds patent covering AstraZeneca’s type II diabetes drugs Onglyza® and Kombiglyze® valid in ANDA litigation District court finds patent covering AstraZeneca’s type II diabetes drugs Onglyza® and Kombiglyze® valid in ANDA litigation
1:14-cv-00664, D. Del., Judge Sleet
IPR2015-01340, PTAB, Judges Elluru, Paulraj, Tierney
Experience
Shionogi Pharmaceuticals v. Apotex/Sandoz Shionogi Pharmaceuticals v. Apotex/Sandoz
3:15-cv-00668, D.N.J., Judges Goodman, Sheridan
3:12-cv-07907, D.N.J., Judges Goodman, Hillman, Williams, Wolfson
Experience
AstraZeneca Pharmaceuticals LP, Shionogi Co. v. Watson Pharmaceuticals, Inc. AstraZeneca Pharmaceuticals LP, Shionogi Co. v. Watson Pharmaceuticals, Inc.
1:10-cv-00915, D. Del., Judge Stark
Experience
U.S. Court finds patent covering AstraZeneca’s anti-cholesterol drug Crestor®, is valid and enforceable in ANDA litigation U.S. Court finds patent covering AstraZeneca’s anti-cholesterol drug Crestor®, is valid and enforceable in ANDA litigation
1:08-md-01949, D. Del., Judges Farnan, Stark
10-1460, -1461, -1462, -1463, -1464, -1465, -1466, -1467, -1468, -1469, -1470, -1471, -1472, -1473, Fed. Cir., Judges Mayer, Newman, Plager
Experience
Aventis Pharma SA v. Amphastar Pharmaceuticals Inc. Aventis Pharma SA v. Amphastar Pharmaceuticals Inc.
5:03-cv-00887, C.D. Cal., Judges Pfaelzer, Timlin, Abrams, Larson
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.